Skip to content
PubMed This is a summary of 20 peer-reviewed journal articles Updated
Cardiology

Naxos Disease: A Patient Guide

At a Glance

Naxos disease is an inherited condition linked to JUP gene changes that causes woolly hair and thickened palms and soles in childhood. Heart problems may appear later, so early recognition supports lifelong heart monitoring, safer activity choices, and treatment when needed.

Naxos disease is a rare, inherited condition that acts as a bridge between the health of the skin and the strength of the heart. It belongs to a group of conditions known as cardiocutaneous syndromes, where visible signs on the outside of the body provide critical clues about what may happen on the inside [1][2]. While a diagnosis can be daunting, the unique way Naxos disease progresses offers an opportunity to initiate cardiac surveillance before heart symptoms begin, though it does not guarantee the prevention of future issues [3][4].

The Classic Triad

Doctors identify Naxos disease by looking for three specific features that typically appear in a sequence, though they are not always all present at the time of assessment [1][2]:

  1. Woolly Hair: Often the very first sign, babies are frequently born with or soon develop hair that is unusually tightly curled, fine, and sometimes fragile [1].
  2. Palmoplantar Keratoderma: As a child begins to crawl and walk, the skin on their palms and the soles of their feet begins to thicken significantly [5]. This happens because the “cellular glue” (desmosomes) that holds skin cells together is weaker than normal due to a change in the JUP gene [6][7].
  3. Arrhythmogenic Cardiomyopathy (ACM), historically called ARVC: This is the heart-related part of the condition. Over time, the same weak “cellular glue” in the heart muscle can cause cells to pull apart under stress. The body repairs this by replacing muscle with fatty or fibrous scar tissue, which can disrupt the heart’s electrical rhythm [2][7].

The Disease Timeline

One of the most important things for parents to understand is that Naxos disease follows a childhood-to-adulthood timeline. The skin and hair changes are almost always present in early childhood, while the heart issues often do not become clinically apparent until adolescence or young adulthood [1][8]. Because the hair and skin signs are visible so early, they serve as a prompt for doctors to begin heart monitoring long before a teenager might experience palpitations or fainting [3][9].

The Pillars of Management

Managing Naxos disease is a lifelong journey focused on preservation and prevention. Your care will be built on four essential pillars:

  • Proactive Heart Monitoring: Since heart involvement is age-dependent, lifelong surveillance is necessary. This includes regular ECGs, Holter monitors (24-hour heart recordings), and cardiac MRIs to detect the earliest signs of muscle changes or rhythm disturbances [10][3].
  • Exercise Restriction: This is perhaps the most critical “treatment.” High-intensity, competitive, or endurance sports put immense mechanical strain on the heart’s fragile “cellular glue,” which can trigger dangerous arrhythmias and speed up the progression of the disease [11][12]. While low-intensity activity is often encouraged, high-intensity exercise and sports are strongly discouraged for affected individuals to protect the heart muscle [13][14].
  • Medical Protection: Many patients are prescribed beta-blockers to lower the heart’s workload and shield it from adrenaline-triggered rhythms [15][16]. In higher-risk cases, an Implantable Cardioverter-Defibrillator (ICD) may be recommended to provide 24/7 protection against sudden cardiac events [17][18].
  • Family Screening: Because Naxos disease is autosomal recessive (meaning a child inherits one mutated gene from each parent), siblings have a 25% chance of being affected (two mutated copies), a 50% chance of being a carrier (one mutated copy), and a 25% chance of inheriting neither [16]. Genetic counseling and clinical heart screening for siblings are essential parts of family care [10][19].

By identifying Naxos disease early through its unique skin and hair features, you and your medical team can implement these protective strategies years in advance, focusing on a future of proactive health rather than reactive treatment [5][20].

Common questions in this guide

What are the earliest signs of Naxos disease?
Woolly, tightly curled hair often appears in infancy or early childhood. Thickened skin on the palms and soles usually develops as a child begins crawling or walking, while heart problems may not become noticeable until adolescence or young adulthood.
Why does Naxos disease require heart monitoring if there are no symptoms?
Naxos disease can weaken the connections between heart muscle cells and later cause abnormal rhythms before symptoms are obvious. Regular electrocardiograms (ECGs), Holter monitors, and cardiac MRI can help the care team identify heart changes early.
Can a person with Naxos disease play sports or exercise?
High-intensity, competitive, and endurance sports are strongly discouraged because they can strain the heart and increase the risk of dangerous rhythms. Some low-intensity activities may be appropriate, but the cardiology team should define safe options for each person.
How is Naxos disease inherited, and what does it mean for siblings?
Naxos disease follows autosomal recessive inheritance, so a child must inherit one changed JUP gene copy from each parent to be affected. When both parents carry a changed copy, each sibling has a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of inheriting neither changed copy.
What treatments can help protect the heart in Naxos disease?
Lifelong heart surveillance and avoiding high-intensity exercise are central parts of care. Doctors may prescribe beta-blockers to reduce the heart's workload, and an implantable cardioverter-defibrillator may be recommended for people at higher risk of a dangerous rhythm.

Get notified when new evidence is published on Naxos disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (20)
  1. 1

    Naxos Disease and Related Cardio-Cutaneous Syndromes.

    Protonotarios A, Asimaki A, Basso C, et al.

    JACC. Advances 2025; (4(2)):101547 doi:10.1016/j.jacadv.2024.101547.

    PMID: 39877668
  2. 2

    Cardiocutaneous syndrome (Naxos disease) in a Bangladeshi boy.

    Islam AM, Rahman MT, Chowdhury AH

    Cardiovascular diagnosis and therapy 2016; (6(5)):462-465 doi:10.21037/cdt.2016.03.07.

    PMID: 27747171
  3. 3

    Imaging Naxos disease and related cardiocutaneous syndromes: the NAXCARE multimodality approach.

    Protonotarios I, Alsergani H, Anastasakis A, et al.

    Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese 2026; doi:10.1016/j.hjc.2026.03.007.

    PMID: 41936932
  4. 4

    Combination of palmoplantar keratoderma and hair shaft anomalies, the warning signal of severe arrhythmogenic cardiomyopathy: a systematic review on genetic desmosomal diseases.

    Polivka L, Bodemer C, Hadj-Rabia S

    Journal of medical genetics 2016; (53(5)):289-95 doi:10.1136/jmedgenet-2015-103403.

    PMID: 26399581
  5. 5

    Naxos disease: current insights from early clinical observations to genetics and precision medicine.

    Xylouri Z, Al-Sergani H, Protonotarios I, et al.

    Internal and emergency medicine 2026; doi:10.1007/s11739-026-04559-9.

    PMID: 42932075
  6. 6

    Normalization of Naxos plakoglobin levels restores cardiac function in mice.

    Zhang Z, Stroud MJ, Zhang J, et al.

    The Journal of clinical investigation 2015; (125(4)):1708-12.

    PMID: 25705887
  7. 7

    Genetics of and pathogenic mechanisms in arrhythmogenic right ventricular cardiomyopathy.

    Vimalanathan AK, Ehler E, Gehmlich K

    Biophysical reviews 2018; (10(4)):973-982 doi:10.1007/s12551-018-0437-0.

    PMID: 29995277
  8. 8

    Arrhythmogenic right ventricular cardiomyopathy in patients with biallelic JUP-associated skin fragility.

    Vahidnezhad H, Youssefian L, Faghankhani M, et al.

    Scientific reports 2020; (10(1)):21622 doi:10.1038/s41598-020-78344-9.

    PMID: 33303784
  9. 9

    Desmoplakin mutations with palmoplantar keratoderma, woolly hair and cardiomyopathy.

    Pigors M, Schwieger-Briel A, Cosgarea R, et al.

    Acta dermato-venereologica 2015; (95(3)):337-40 doi:10.2340/00015555-1974.

    PMID: 25227139
  10. 10

    Genotype and cardiac outcome in patients with cardiocutaneous syndrome (Naxos disease variant: Carvajal syndrome).

    Binfadel M, Aleem MU, Alhabdan M, et al.

    Orphanet journal of rare diseases 2025; (20(1)):137 doi:10.1186/s13023-025-03612-8.

    PMID: 40108711
  11. 11

    Harmful Effects of Exercise Intensity and Exercise Duration in Patients With Arrhythmogenic Cardiomyopathy.

    Lie ØH, Dejgaard LA, Saberniak J, et al.

    JACC. Clinical electrophysiology 2018; (4(6)):744-753 doi:10.1016/j.jacep.2018.01.010.

    PMID: 29929667
  12. 12

    Physical Activity in Arrhythmogenic Cardiomyopathy: From Trigger to Therapeutic Dilemma.

    Kayvanpour E, Meder B, Sedaghat-Hamedani F

    Reviews in cardiovascular medicine 2026; (27(8)):52871 doi:10.31083/RCM52871.

    PMID: 42694556
  13. 13

    Arrhythmogenic Cardiomyopathy in 2018-2019: ARVC/ALVC or Both?

    Bennett RG, Haqqani HM, Berruezo A, et al.

    Heart, lung & circulation 2019; (28(1)):164-177 doi:10.1016/j.hlc.2018.10.013.

    PMID: 30446243
  14. 14

    Arrhythmogenic right ventricular cardiomyopathy and sports activity: from molecular pathways in diseased hearts to new insights into the athletic heart mimicry.

    Gasperetti A, James CA, Cerrone M, et al.

    European heart journal 2021; (42(13)):1231-1243 doi:10.1093/eurheartj/ehaa821.

    PMID: 33200174
  15. 15

    Arrhythmogenic Cardiomyopathy: Electrical and Structural Phenotypes.

    Akdis D, Brunckhorst C, Duru F, Saguner AM

    Arrhythmia & electrophysiology review 2016; (5(2)):90-101 doi:10.15420/AER.2016.4.3.

    PMID: 27617087
  16. 16

    Naxos disease - a narrative review.

    Leopoulou M, Mattsson G, LeQuang JA, et al.

    Expert review of cardiovascular therapy 2020; (18(11)):801-808 doi:10.1080/14779072.2020.1828064.

    PMID: 32966140
  17. 17

    Arrhythmogenic Cardiomyopathy-Current Treatment and Future Options.

    Migliore F, Mattesi G, Zorzi A, et al.

    Journal of clinical medicine 2021; (10(13)) doi:10.3390/jcm10132750.

    PMID: 34206637
  18. 18

    A Case of Left-Dominant Arrhythmogenic Cardiomyopathy Presenting with Cardiac Arrest.

    Piya S, Jackson A, Coats CJ, Nordin S

    British journal of hospital medicine (London, England : 2005) 2025; (86(3)):1-12 doi:10.12968/hmed.2024.0674.

    PMID: 40135302
  19. 19

    [Genetic diagnostics for cardiomyopathies].

    Czepluch F, Wollnik B, Hasenfuß G

    Deutsche medizinische Wochenschrift (1946) 2017; (142(9)):657-664 doi:10.1055/s-0042-112183.

    PMID: 28454199
  20. 20

    Clinical and Molecular Aspects of Naxos Disease.

    Protonotarios I, Asimaki A, Xylouri Z, et al.

    Heart failure clinics 2022; (18(1)):89-99 doi:10.1016/j.hfc.2021.07.010.

    PMID: 34776086

This page is for informational purposes only and does not constitute medical advice. It cannot replace guidance from your cardiology, dermatology, or genetics team about heart screening, exercise limits, genetic testing, or treatment.